KBC Group
STOK icon

KBC Group’s Stoke Therapeutics STOK Stock Holding History

KBC Group’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$28K Hold
1,096
– – ﹤0.01% 1809
2026
Q2 		$36K Hold
1,096
– – ﹤0.01% 1794
2026
Q1 		$36K Buy
+1,096
New +$35.9K ﹤0.01% 1752

Other funds holding STOK

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
SYM Financial Corp
SYM Financial Corp Winona Lake, Indiana $1.31B AUM 18.92% 1-Year Est. Return
Moran Wealth Management
Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Harbor Capital Advisors
Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Generali Investments Management
Generali Investments Management Ljubljana, Slovenia $517M AUM 27.81% 1-Year Est. Return
Yorktown Management & Research Company
Yorktown Management & Research Company Forest, Virginia $150M AUM 39.02% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

KBC Group's STOK Position: Q3 2026 in Review

KBC Group held its Stoke Therapeutics (STOK) position steady in Q3 2026 at 1,096 shares worth $28K. The position accounts for ﹤0.01% of the portfolio, ranked #1809.

KBC Group first reported a position in STOK in Q1 2026 and has held it in 3 quarters since. The position peaked at $36K in Q2 2026. 28 funds tracked by Wall St. Rank hold STOK as of Q3 2026.

  • KBC Group held 1,096 shares of Stoke Therapeutics worth $28K as of Q3 2026.
  • KBC Group left its Stoke Therapeutics share count unchanged in Q3 2026.
  • Stoke Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1809 holding.
  • KBC Group first reported a position in Stoke Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • KBC Group's Stoke Therapeutics position peaked at $36K in Q2 2026.
  • 28 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.